SG10202101887WA - Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof - Google Patents

Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Info

Publication number
SG10202101887WA
SG10202101887WA SG10202101887WA SG10202101887WA SG10202101887WA SG 10202101887W A SG10202101887W A SG 10202101887WA SG 10202101887W A SG10202101887W A SG 10202101887WA SG 10202101887W A SG10202101887W A SG 10202101887WA SG 10202101887W A SG10202101887W A SG 10202101887WA
Authority
SG
Singapore
Prior art keywords
conjugates
methods
group
immunogenic compositions
producing
Prior art date
Application number
SG10202101887WA
Inventor
Annaliesa Sybil Anderson
Bhalla Amardeep Singh Bhupender
Robert G K Donald
Jianxin Gu
Kathrin Ute Jansen
Rajesh Kumar Kainthan
Lakshmi Khandke
Jin-Hwan Kim
Paul Liberator
Avvari Krishna Prasad
Mark Edward Ruppen
Ingrid Lea Scully
Suddham Singh
Cindy Xudong Yang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG10202101887WA publication Critical patent/SG10202101887WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Sustainable Development (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SG10202101887WA 2015-05-04 2016-04-29 Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof SG10202101887WA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562156500P 2015-05-04 2015-05-04
US201562237813P 2015-10-06 2015-10-06
US201562237820P 2015-10-06 2015-10-06
US201662319539P 2016-04-07 2016-04-07

Publications (1)

Publication Number Publication Date
SG10202101887WA true SG10202101887WA (en) 2021-03-30

Family

ID=55967339

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201708242YA SG11201708242YA (en) 2015-05-04 2016-04-29 Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
SG10202101887WA SG10202101887WA (en) 2015-05-04 2016-04-29 Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201708242YA SG11201708242YA (en) 2015-05-04 2016-04-29 Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Country Status (21)

Country Link
US (4) US10226525B2 (en)
EP (1) EP3292146A1 (en)
JP (3) JP6948951B2 (en)
KR (2) KR102143534B1 (en)
CN (2) CN114010775A (en)
AU (2) AU2016258284C1 (en)
BR (1) BR112017022776A2 (en)
CA (1) CA2928602A1 (en)
CO (1) CO2017011245A2 (en)
IL (2) IL297740A (en)
MX (1) MX368897B (en)
MY (1) MY182282A (en)
NZ (1) NZ736238A (en)
PE (2) PE20180172A1 (en)
PH (1) PH12017501898A1 (en)
RU (1) RU2692923C2 (en)
SA (1) SA517390274B1 (en)
SG (2) SG11201708242YA (en)
TW (2) TWI807252B (en)
WO (1) WO2016178123A1 (en)
ZA (1) ZA201807203B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
CA2923129C (en) * 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RU2710393C2 (en) * 2014-01-21 2019-12-26 Пфайзер Инк. Method of producing immunogenic conjugate of capsular polysaccharide streptococcus pneumoniae-carrier protein
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL297740A (en) 2015-05-04 2022-12-01 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CN108144052A (en) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 Streptococcus pneumoniae polysaccharides-protein conjugate and its preparation method and purposes
EP3568157A4 (en) * 2017-01-13 2021-01-06 National Research Council of Canada Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines
CN116870144A (en) 2017-01-31 2023-10-13 默沙东有限责任公司 Method for preparing polysaccharide-protein conjugates
AU2018225083B2 (en) * 2017-02-24 2023-06-01 Merck Sharp & Dohme Llc Pneumococcal conjugate vaccine formulations
BR112019017560A2 (en) 2017-02-24 2020-04-07 Merck Sharp & Dohme enhancement of immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
EP3668541A4 (en) * 2017-08-16 2021-05-26 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
MX2020002557A (en) 2017-09-07 2020-07-13 Merck Sharp & Dohme Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates.
CA3074714A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
CN111065387B (en) 2017-09-07 2023-08-25 默沙东有限责任公司 Pneumococcal polysaccharide and its use in immunogenic polysaccharide-carrier protein conjugates
GEP20227420B (en) 2017-12-06 2022-10-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
EP3787673A4 (en) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
KR102120830B1 (en) * 2018-09-20 2020-06-09 고려대학교산학협력단 Novel Group B Streptococcus Serotype Strain and Immunogenic Composition Comprising the Same
JOP20210148A1 (en) 2018-12-19 2023-01-30 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3139257A1 (en) * 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
CN112741901B (en) * 2019-10-31 2024-05-10 北京科兴中维生物技术有限公司 Vaccine containing streptococcus pneumoniae capsular polysaccharide type 5 and preparation method thereof
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20230303637A1 (en) 2020-06-12 2023-09-28 Glaxosmithkline Biologicals Sa Gbs ferritin nanoparticles
JP2023529925A (en) 2020-06-12 2023-07-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Bacterial immunization using nanoparticle vaccines
CN114073761B (en) * 2020-08-11 2023-11-14 山东大学 Oligosaccharide conjugate and application thereof as saccharide vaccine for preventing group V-B streptococcus infection
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN112939164B (en) * 2021-03-15 2022-05-24 广西大学 Method for disinfecting marine aquaculture water
TW202306969A (en) * 2021-05-28 2023-02-16 美商輝瑞大藥廠 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN113480622A (en) * 2021-08-05 2021-10-08 江苏坤力生物制药有限责任公司 Method for preparing and purifying recombinant pneumolysin
CN113651730A (en) * 2021-08-20 2021-11-16 宿迁盛瑞新材料有限公司 Preparation method of bis (octadecyl) hydroxylamine
CN115960962A (en) * 2021-10-09 2023-04-14 江苏金斯瑞蓬勃生物科技有限公司 Protective agent for enhancing stability of lentivirus vector and application thereof
CN113621089B (en) * 2021-10-11 2021-12-17 山东洁壹选生物科技有限公司 Preparation method and application of algal polysaccharide extract
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
CN114015622A (en) * 2021-12-14 2022-02-08 塔里木大学 Streptococcus agalactiae culture medium and preparation method thereof

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
SE8405493D0 (en) 1984-11-01 1984-11-01 Bror Morein IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
IT1253009B (en) 1991-12-31 1995-07-10 Sclavo Ricerca S R L DETOXIFIED IMMUNOGENIC MUTANTS OF COLERIC TOXIN AND TOXIN LT, THEIR PREPARATION AND USE FOR THE PREPARATION OF VACCINES
CA2129899C (en) 1992-02-11 2011-01-04 James J. Mond Dual carrier immunogenic construct
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
IL107103A (en) * 1992-09-24 2001-03-19 Brigham & Womens Hospital Multivalent vaccine based on conjugated molecule comprising a capsular polysaccharide linked to a protein and a method for the preparation thereof
ES2231770T3 (en) 1993-03-05 2005-05-16 Wyeth Holdings Corporation NEW PLASMIDS FOR THE PRODUCTION OF CRM PROTEIN AND DIFTERIC TOXIN.
JP3828145B2 (en) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン A method for the activation of soluble carbohydrates using a novel cyanating reagent for the production of immunogenic components
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
BE1008978A5 (en) 1994-12-27 1996-10-01 Solvay Adjuvants for vaccines.
ATE241384T1 (en) 1995-03-22 2003-06-15 Jackson H M Found Military Med PREPARATION OF IMMUNOGENIC CONSTRUCTS USING SOLUBLE CARBOHYDRATES ACTIVATED BY ORGANIC CYANYLATION REAGENTS
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US20010051364A1 (en) * 1997-12-23 2001-12-13 Francis Michon Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
DE69841676D1 (en) * 1997-12-23 2010-07-01 Baxter Healthcare Sa PROCESS FOR EXTRACTION AND ISOLATION OF BACTERIAL HOLLOW POLYSACCHARIDES FOR USE AS VACCINE OR COUPLED TO PROTEINS AS CONJUGATED VACCINE
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
SK287689B6 (en) 2000-06-08 2011-06-06 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410635B (en) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh VACCINE COMPOSITION
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (en) 2001-06-07 2007-06-13 惠氏控股有限公司 Mutant forms of cholera holotoxin as an adjuvant
TWI313609B (en) 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
AU2004220590B2 (en) 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
DE602004017864D1 (en) * 2003-06-23 2009-01-02 Baxter Int CARRIER PROTEINS FOR VACCINES
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0411387D0 (en) * 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
JP5049264B2 (en) 2005-04-08 2012-10-17 ワイス・エルエルシー Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102716480B (en) 2005-04-08 2023-03-21 惠氏有限责任公司 Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
CA2808919C (en) 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
CL2007002909A1 (en) 2006-10-10 2008-04-18 Wyeth Corp METHOD FOR REDUCTION OR EXTRACTION OF IMPURITIES OF PROTEINS FROM STREPTOCCOCUS PNEUMONIAE CELLULAR THAT INCLUDES HEATING THIS LISADO, SEPARATE PRECIPITANTS FROM LISADO LISADO PRODUCING A LISAC
HUE039169T2 (en) 2007-03-23 2018-12-28 Wyeth Llc Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
EP2687228B1 (en) * 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5453461B2 (en) 2009-03-05 2014-03-26 インターデイジタル パテント ホールディングス インコーポレイテッド Methods and equipment for H (e) NB integrity verification and validation
JP2012530785A (en) * 2009-06-22 2012-12-06 ワイス・エルエルシー Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2011080570A2 (en) 2009-12-29 2011-07-07 Micro Labs Limited Extended release pharmaceutical composition comprising linezolid and process for preparing the same
JP2013538211A (en) * 2010-08-23 2013-10-10 セレクタ バイオサイエンシーズ インコーポレーテッド Targeted multi-epitope dosage forms that elicit an immune response to an antigen
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US9120848B2 (en) 2010-09-23 2015-09-01 Harvey Kaplan Non-aqueous synthesis of polysaccharide-protein conjugates for vaccines
WO2012061400A2 (en) 2010-11-01 2012-05-10 University Of Maryland, Baltimore Method for reduction of free polysaccharide in polysaccharide-protein vaccines reactions using ion-exchange matrices
GB201121301D0 (en) * 2011-12-12 2012-01-25 Novartis Ag Method
JP2015510872A (en) 2012-03-07 2015-04-13 ノバルティス アーゲー Enhanced formulation of Streptococcus pneumoniae antigen
KR102057217B1 (en) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
HUE041381T2 (en) * 2012-08-16 2019-05-28 Pfizer Glycoconjugation processes and compositions
US9636392B2 (en) 2012-09-07 2017-05-02 Sk Chemical Co., Ltd. Production method for capsular polysaccharide having pneumococcal serotype
EA201590427A1 (en) 2012-10-02 2015-09-30 Глаксосмитклайн Байолоджикалс С.А. NONLINEAR SUCHARIDE CONJUGATES
US9855324B2 (en) * 2012-10-03 2018-01-02 Glaxosmithkline Biologicals Sa Immunogenic compositions
KR20140075196A (en) 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20140075201A (en) 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2014097099A2 (en) 2012-12-20 2014-06-26 Pfizer Inc. Glycoconjugation process
WO2015084867A1 (en) * 2013-12-02 2015-06-11 Brandeis University Multivalent glycopeptides that tightly bind to target proteins
PL3096785T3 (en) * 2014-01-21 2021-03-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PL3583947T3 (en) * 2014-01-21 2024-04-02 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP3443983B1 (en) * 2014-02-14 2022-07-20 Pfizer Inc. Immunogenic glycoprotein conjugates
US10150979B2 (en) * 2014-05-07 2018-12-11 Glaxosmithkline Biologicals Sa Purification of secreted polysaccharides from S. agalactiae
TWI583284B (en) * 2015-02-06 2017-05-11 鴻海精密工業股份有限公司 Protective shell
IL297740A (en) * 2015-05-04 2022-12-01 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
BR112017026343A2 (en) 2015-06-08 2019-11-19 Serum Inst Of India Private Ltd methods for improving the adsorption of protein-polysaccharide conjugates and thus obtained multivalent vaccine formulation
EP3518965A1 (en) 2016-09-30 2019-08-07 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
US10751402B2 (en) * 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
BR112019022868A2 (en) * 2017-05-05 2020-05-19 Serum Institute Of India Private Limited method for removing impurities from preparations based on bacterial capsular polysaccharide

Also Published As

Publication number Publication date
MX368897B (en) 2019-10-21
SG11201708242YA (en) 2017-11-29
EP3292146A1 (en) 2018-03-14
US20160324950A1 (en) 2016-11-10
CA2928602A1 (en) 2016-11-04
KR102143534B1 (en) 2020-08-12
JP6948951B2 (en) 2021-10-13
AU2019202680B2 (en) 2020-05-14
RU2017136859A (en) 2019-06-04
MX2017014127A (en) 2018-03-01
IL297740A (en) 2022-12-01
US20190142922A1 (en) 2019-05-16
RU2017136859A3 (en) 2019-06-04
AU2016258284C1 (en) 2020-09-03
PE20180172A1 (en) 2018-01-22
KR20190128264A (en) 2019-11-15
TWI718144B (en) 2021-02-11
TWI807252B (en) 2023-07-01
PE20220774A1 (en) 2022-05-16
JP2018514571A (en) 2018-06-07
NZ736238A (en) 2022-07-01
CN114010775A (en) 2022-02-08
IL255106B2 (en) 2023-04-01
IL255106A0 (en) 2017-12-31
TW202135856A (en) 2021-10-01
JP2022008445A (en) 2022-01-13
JP2024009978A (en) 2024-01-23
AU2016258284B2 (en) 2019-01-17
IL255106B (en) 2022-12-01
CO2017011245A2 (en) 2018-03-28
CN107624070A (en) 2018-01-23
US10946086B2 (en) 2021-03-16
TW201704254A (en) 2017-02-01
SA517390274B1 (en) 2022-12-22
PH12017501898A1 (en) 2018-03-05
RU2692923C2 (en) 2019-06-28
ZA201807203B (en) 2022-05-25
MY182282A (en) 2021-01-18
AU2016258284A1 (en) 2017-11-02
KR20170138568A (en) 2017-12-15
AU2019202680A1 (en) 2019-05-09
US20230346903A1 (en) 2023-11-02
BR112017022776A2 (en) 2018-07-10
WO2016178123A1 (en) 2016-11-10
KR102045663B1 (en) 2019-11-15
US20210145957A1 (en) 2021-05-20
US10226525B2 (en) 2019-03-12

Similar Documents

Publication Publication Date Title
ZA201807203B (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
IL297575B1 (en) Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
ZA201903620B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
IL264552A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
IL256558B (en) Antibody-drug conjugate compositions and methods for producing same
IL252915A0 (en) Immunogenic compositions for use in pneumococcal vaccines
IL264553A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
IL248239A0 (en) Anti - her3 antibody - drug conjugates, compositions comprising same and uses thereof
SG11201706426YA (en) Modified conjugated diene-based polymer and method for producing the same, and modified conjugated diene-based polymer composition
EP3356595C0 (en) Processes for producing nanocellulose, and nanocellulose compositions produced therefrom
ZA201708713B (en) Multivalent pneumococcal conjugate vaccine
EP3142695A4 (en) Compositions and methods of enhancing immunogenicity of polysaccharide-protein conjugates
GB201610599D0 (en) Immunogenic Composition
EP3193919A4 (en) Immunogenic/therapeutic glycoconjugate compositions and uses thereof
HK1213800A1 (en) Toxoid, compositions and related methods
GB201711635D0 (en) Immunogenic composition
EP3075393A4 (en) Adjuvant composition, vaccine composition comprising same, and method for producing same
HK1247927A1 (en) Novel compositions, uses and methods for making them
GB201711637D0 (en) Immunogenic composition
GB201614485D0 (en) Immunogenic composition
EP3199526A4 (en) Intermediate for use in synthesizing paroxetine, preparation method for the intermediate, and uses thereof
SG11201609761YA (en) Conjugated diene-based polymer, method for producing the same, and composition including the same
EP2951226A4 (en) Triblock copolymer, method for its formation, and compatibilized compositions comprising it
HK1213917A1 (en) Toxoid, compositions and related methods
GB2570806B (en) Immunogenic agent and associated compositions, uses and methods